Takeshi leads H3’s team of Scientific Operations and was one of the founding members of H3 Biomedicine in 2011, with key contributions to the creation and build-out of key corporate elements and functions. Currently, he is responsible for the management of the entire program portfolio of the company, ranging from discovery to the clinic. Takeshi’s group provides program management and strategic support to all of H3’s programs and platforms. Takeshi began his professional career as a research scientist in drug metabolism and pharmacokinetics at Eisai and contributed to two investigational new drug (IND) filings attained by the team during his tenure. He then transitioned into R&D management after completing his M.B.A. Prior to joining H3, Takeshi served as Senior Director of Portfolio Management for Eisai’s Oncology Business Group where he led portfolio optimization and program prioritization.
Takeshi received his M.B.A. from the Kellogg School of Management at Northwestern University and his Ph.D. and B.A., both in pharmaceutical sciences, from the University of Tokyo.